![JAMA Ophthalmology Author Interviews artwork](https://is3-ssl.mzstatic.com/image/thumb/Podcasts123/v4/bd/bd/7b/bdbd7bcb-c943-5b87-b75e-b0d1f0a16a39/mza_13791991983730085614.png/100x100bb.jpg)
Cost-effectiveness of Aflibercept vs Bevacizumab-First Therapy for Diabetic Macular Edema
JAMA Ophthalmology Author Interviews
English - February 02, 2023 16:00 - 13 minutes - 29.9 MB - ★★★★ - 5 ratingsMedicine Health & Fitness Science ophthalmology eyes jamanetwork vision Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Interview with David W. Hutton, PhD, author of Cost-effectiveness of Aflibercept Monotherapy vs Bevacizumab First Followed by Aflibercept If Needed for Diabetic Macular Edema. Hosted by Neil Bressler, MD.